Amphiphilic PEGylated Lanthanide-Doped Upconversion Nanoparticles for Significantly Passive Accumulation in the Peritoneal Metastatic Carcinomatosis Models Following Intraperitoneal Administration
Source abstract
Abstract
Inorganic nanoparticles have emerged as attractive materials for cancer research, because of their exceptional physical properties and multifunctional engineering. However, inorganic nanoparticle accumulation in the tumors located in the abdominal cavity after intravenous (IV) administration is confined because of the peritoneum-plasma barrier. To improve this situation, we developed lanthanide-doped upconversion nanoparticles (UCNPs), coated by amphiphilic polyethylene glycol (P-PEG), serving as a representative of inorganic nanoparticles. Following intraperitoneal (IP) administration into the peritoneal metastatic carcinomatosis models, UCNPs coated by P-PEG (P-PEG-UCNPs) passively accumulated in the cancerous tissues at a larger amount than that in the main normal organs. On the basis of spatial proximity, P-PEG-UCNPs administrated via the IP route exhibited higher passive accumulation in the tumors in the abdominal cavity compared to that via the IV route. It is suggested that IP administration could be a promising strategy for inorganic nanoparticles to be efficaciously applied in peritoneal cancer research.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Luminescence Properties of Advanced Materials · Nanoplatforms for cancer theranostics · Intraperitoneal and Appendiceal Malignancies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry & Institute of Biomedicine Science & State Key Laboratory of Molecular Engineering of polymers, Fudan University, 220 Handan Road, Shanghai 200433, P.R. China
College of Chemical and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, P.R. China
Center of Analysis and Measurement, Fudan University, 220 Handan Road, Shanghai 200433, P.R. China
Funding
National Natural Science Foundation of China
References (60)
Show source-provided references
1. 10.1016/j.addr.2012.08.01510.1016/j.addr.2012.08.015 ↗
2. 10.1021/acs.bioconjchem.6b0065410.1021/acs.bioconjchem.6b00654 ↗
3. 10.1021/acs.chemrev.6b0007310.1021/acs.chemrev.6b00073 ↗
4. 10.1016/j.nantod.2012.10.01010.1016/j.nantod.2012.10.010 ↗
5. 10.1039/C5CS00699F10.1039/C5CS00699F ↗
6. 10.1021/acsami.6b0104610.1021/acsami.6b01046 ↗
7. 10.1016/j.pharep.2014.10.01910.1016/j.pharep.2014.10.019 ↗
8. 10.1039/C7NR00078B10.1039/C7NR00078B ↗
9. 10.1016/j.nano.2014.06.00510.1016/j.nano.2014.06.005 ↗
10. 10.1016/j.addr.2016.07.00110.1016/j.addr.2016.07.001 ↗
11. 10.2165/11598890-000000000-0000010.2165/11598890-000000000-00000 ↗
12. 10.1007/s11095-007-9298-010.1007/s11095-007-9298-0 ↗
13. 10.3892/or.2014.321010.3892/or.2014.3210 ↗
14. 10.1111/j.1525-1438.2007.00809.x10.1111/j.1525-1438.2007.00809.x ↗
15. 10.1021/acsbiomaterials.6b0001210.1021/acsbiomaterials.6b00012 ↗
16. 10.1021/acsbiomaterials.6b0025210.1021/acsbiomaterials.6b00252 ↗
17. 10.1039/C5NR08477F10.1039/C5NR08477F ↗
18. 10.1021/cr400478f10.1021/cr400478f ↗
19. 10.1166/jbn.2015.215010.1166/jbn.2015.2150 ↗
20. 10.1002/smll.20177007610.1002/smll.201770076 ↗
21. 10.7150/thno.1410110.7150/thno.14101 ↗
22. 10.1021/acsbiomaterials.6b0060710.1021/acsbiomaterials.6b00607 ↗
23. 10.1021/acsbiomaterials.6b0047310.1021/acsbiomaterials.6b00473 ↗
24. 10.1038/nbt.333010.1038/nbt.3330 ↗
25. 10.1166/jbn.2015.207310.1166/jbn.2015.2073 ↗
26. 10.1166/jnn.2016.1161010.1166/jnn.2016.11610 ↗
27. 10.1021/acsbiomaterials.6b0064510.1021/acsbiomaterials.6b00645 ↗
28. 10.1021/acsbiomaterials.6b0031110.1021/acsbiomaterials.6b00311 ↗
29. 10.1166/jbn.2015.199610.1166/jbn.2015.1996 ↗
30. 10.1021/jp110603r10.1021/jp110603r ↗
31. 10.1021/ja809086q10.1021/ja809086q ↗
32. 10.1016/j.biomaterials.2011.07.05310.1016/j.biomaterials.2011.07.053 ↗
33. 10.1002/adfm.20130213310.1002/adfm.201302133 ↗
34. 10.1002/adhm.20120040610.1002/adhm.201200406 ↗
35. 10.1016/j.jss.2016.05.03410.1016/j.jss.2016.05.034 ↗
36. 10.1016/j.ijpharm.2015.04.06010.1016/j.ijpharm.2015.04.060 ↗
37. 10.1039/C6NR01845A10.1039/C6NR01845A ↗
38. 10.1016/j.biomaterials.2016.07.02310.1016/j.biomaterials.2016.07.023 ↗
39. 10.2147/IJN.S842810.2147/IJN.S8428 ↗
40. 10.1016/j.ejpb.2016.05.01010.1016/j.ejpb.2016.05.010 ↗
41. 10.1016/j.biomaterials.2016.10.00810.1016/j.biomaterials.2016.10.008 ↗
42. 10.1016/j.inoche.2009.12.03110.1016/j.inoche.2009.12.031 ↗
43. 10.1016/j.biomaterials.2010.05.06510.1016/j.biomaterials.2010.05.065 ↗
44. 10.1021/ja207078s10.1021/ja207078s ↗
45. 10.1016/j.biomaterials.2013.05.02810.1016/j.biomaterials.2013.05.028 ↗
46. 10.1039/c4ra01815j10.1039/c4ra01815j ↗
47. 10.1016/j.biomaterials.2012.03.00710.1016/j.biomaterials.2012.03.007 ↗
48. 10.1016/S1002-0721(17)60889-510.1016/S1002-0721(17)60889-5 ↗
49. 10.1021/nn700245810.1021/nn7002458 ↗
50. 10.2217/fon.10.10010.2217/fon.10.100 ↗
51. 10.1002/wnan.145110.1002/wnan.1451 ↗
52. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
53. 10.1016/S1382-6689(98)00025-810.1016/S1382-6689(98)00025-8 ↗
54. 10.1016/j.transproceed.2004.06.02710.1016/j.transproceed.2004.06.027 ↗
55. 10.1016/j.kint.2016.11.01710.1016/j.kint.2016.11.017 ↗
56. 10.1166/jnn.2016.1303210.1166/jnn.2016.13032 ↗
57. 10.1016/j.toxlet.2011.03.02110.1016/j.toxlet.2011.03.021 ↗
58. 10.1021/nl060335010.1021/nl0603350 ↗
59. 10.1016/j.bbrc.2010.02.04610.1016/j.bbrc.2010.02.046 ↗
60. 10.1021/nn102430310.1021/nn1024303 ↗